Rani Therapeutics Holdings, Inc. - Class A Common Stock (RANI)
1.3850
+0.0050 (0.36%)
Rani Therapeutics Holdings Inc. is a biopharmaceutical company focused on developing innovative oral therapies for the delivery of biologics, such as peptides and proteins, which traditionally require injection for administration
The company’s proprietary RaniPill platform utilizes a novel approach to encapsulate and deliver these treatments orally, aiming to enhance patient compliance and accessibility in the administration of complex medications. By combining advanced engineering with pharmaceutical expertise, Rani Therapeutics is exploring solutions that could revolutionize the landscape of therapeutic delivery, making it more patient-friendly.
Rani Therapeutics shares are trading lower by 23% Tuesday afternoon. The company announced a $10 million direct offering of 3 million shares at $3 per share.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Companies Reporting Before The Bell • UP Fintech Holding (NASDAQTIGR) is expected to report quarterly earnings at $0.07 per share on revenue of $207.00 million.
Gainers SciSparc Ltd. (NASDAQSPRC) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million private placement for SciSparc.
Gainers SciSparc Ltd. (NASDAQSPRC) shares surged 79.5% to $5.08 in pre-market trading after falling around 7% on Monday. SciSparc recently regained compliance with the Nasdaq Minimum Bid Price Notification.
